| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Division of Endocrinology (L.S., N.Z.-L., O.B., Z.H.), Meyer Childrens Hospital, Haifa 31096, Israel; Department of Pediatric Endocrinology and Diabetes (A.G., E.M.-T.), Silesian University School of Medicine, 40287 Katowice, Poland; Pediatric Endocrinology (L.G., A.V.), Parma University, 143100 Parma, Italy; Department of Pediatrics (A.B.), Ismir University, 35360 Ismir, Turkey; Pediatric Endocrinology (Y.R., O.A.), Haemek Hospital, Afula 18101, Israel; Department of Pediatrics (T.B.), Asaf Harofeh Hospital, Tzrifin, Israel; Department of Biochemistry and Molecular Genetics (F.F.), Carmel Medical Center, Haifa, Israel; and Faculty of Medicine (F.F., Z.H.), Technion-Israel Institute of Technology, Haifa 31096, Israel
Address all correspondence and requests for reprints to: Zeev Hochberg, Meyer Childrens Hospital, Rambam Medical Center, P.O. Box 9602, Haifa 31096, Israel. E-mail: z_hochberg{at}rambam.health.gov.il.
| Abstract |
|---|
|
|
|---|
Hypothesis: The TS phenotype is influenced by the parental origin of the missed X chromosome.
Design: This was a multicenter prospective study of TS patients and both their parents, determining parental origin of the X-chromosome, and characterizing the clinical phenotype.
Patients and Methods: Eighty-three TS patients and their parents were studied. Inclusion criteria were TS with karyotype 45,X or 46Xi(Xq). Four highly polymorphic microsatellite markers on the X-chromosome DMD49, DYSII, DXS1283, and the androgen receptor gene and three Y chromosome markers, SRY, DYZ1, and DYZ3.
Outcome Measures: The study determined the correlation between the parental origin of the X chromosome and the unique phenotypic traits of TS including congenital malformations, anthropometry and growth pattern, skeletal defects, endocrine traits, education, and vocation.
Results: Eighty-three percent of 45,X retained their maternal X (Xm), whereas 64% 46Xi(Xq) retained their paternal X (Xp, P < 0.001). Kidney malformations were exclusively found in Xm patients (P = 0.030). The Xm group had lower total and low-density lipoprotein cholesterol (P < 0.003), and higher body mass index SD score (P = 0.030) that was not maintained after GH treatment. Response to GH therapy was comparable. Ocular abnormalities were more common in the paternal X group (P = 0.017), who also had higher academic achievement.
Conclusions: The parental origin of the missing short arm of the X chromosome has an impact on overweight, kidney, eye, and lipids, which suggests a potential effect of an as-yet-undetermined X chromosome gene imprinting.
| Introduction |
|---|
|
|
|---|
The phenotype in TS is variable even in patients with a supposedly nonmosaic karyotype; the reasons for this variability are not clear, and it led to a speculation that the TS phenotype may be influenced by the parental origin of the retained X chromosome. Differences in physical or behavioral phenotype between subjects with 45, Xp and 45, Xm TS might therefore indicate the existence of imprinted genetic loci leading to expression of genes from only one of the parents who transmits them.
The parental origin of the X chromosome in TS has been the subject of several studies (3, 4, 5, 6, 7, 8). Results of most, but not all, of these small and retrospective studies show that in the majority of patients the Xp chromosome is lost; thus, 6080% of TS patients retain a Xm. Interestingly, aborted fetuses have higher incidence of Xp, suggesting that genetic imprinting may play an important role in the loss of TS fetuses (9).
Three studies correlated birth weight and height as well as other physical, anatomical, and physiological parameters in 33, 25, and 40 TS patients and found no significant differences in patients who retained the maternal or the paternal X chromosome (8, 10, 11). Tsezou et al. (8) also reported no difference between the groups regarding growth during the first and second year of GH therapy. On the other hand, Chu et al. (12) found that imprinting may play a role in cardiovascular anomalies and neck webbing but not renal anomalies. Skuse et al. (13) investigated 80 girls with TS, of whom 25 had an X chromosome of paternal origin, and found evidence for a difference in sociocognitive function between Xm and Xp. The latter showed satisfactory social adjustment and had higher verbal and executive functional skills, whereas Xm patients had better visual-spatial memory tests.
Different phenotypes according to the parental origin of the X chromosome may indicate X imprinting, which has not been documented in humans so far. On the other hand, mice show X-linked imprinting effects on cognitive processes (14), the imprinted gene candidate being Xlr3b, which may be of importance in mediating behavioral effects.
The present study attempted to identify the phenotypic effects of possible X-linked imprinted genes in a large group of 83 TS patients who definitely miss the Xp arm (66 monosomic 45,X females and 14 with iso-Xq). We determined the parental origin of the retained X chromosome, subdivided the patients by the karyotype and compared in these groups the frequency of the unique phenotypic traits of TS, including congenital malformations, anthropometry and growth pattern, skeletal defects, endocrine traits, education, and vocation, thus testing the hypothesis that 45, Xp would be distinguished from 45, Xm. This may direct future research to the putative X-linked imprinted gene/genes on the Xp arm that may contribute to an eventual phenotypic variability according to parental origin.
| Patients and Methods |
|---|
|
|
|---|
Patients and clinical assessment
The study group included 83 patients with TS and their parents in a multicenter study, involving patients from Israel (28), Poland (39), Italy (10), and Turkey (6). The mean (±SD) patients age was 15.1 ± 7.0 yr (range 0.439 yr). The patients were recruited during the year 2003 from the participating centers. Inclusion criteria were the following: karyotype 45,X or 46Xi(Xq); patients with mosaics, ring, or Y chromosomes were excluded; availability of samples of both parents and their consent to participate in the study. Each patient was reexamined by the coordinating physician in each center. Physical stigmata diagnosed on the basis of radiologic examinations such as echocardiogram, renal ultrasonography, and dual-energy x-ray absorptiometry (DXA) studies were collected retrospectively. Biochemical studies were done either prospectively or within the last year. Complete clinical, anatomical, and biochemical information was recorded in a table including more than 100 criteria and then evaluated by a single coordinator for the purpose of a unified evaluation in different centers.
X chromosome origin
Genomic DNA from TS patients and both their parents was extracted from peripheral leukocytes of all 83 families. Four highly polymorphic microsatellite markers were selected for their high percentage of heterozygosity (80.493.3%), their allele number (8, 10, 11, 12, 13, 15, 16, 17, 18, 19, 20), and their location on both Xp and Xq, and were amplified by PCR: DMD49 (Xp21.2), DYSII (Xp21.2), and DXS1283 (Xp22.3) and androgen receptor (Xq11.2). To detect possible hidden Y chromosome mosaics, three Y markers were selected for their location on Yp, centromer, and Yq; SRY, DYZ1, and DYZ3 markers were amplified by PCR. Internal controls (DYSII with SRY, IR5 with DYZ1 and DYZ3) were simultaneously amplified in a multiplex PCR. Female personnel carried out all experiments to prevent false-positive results. Primers and amplification conditions were as previously reported (7).
Statistical analysis
All statistical calculations were performed with SPSS for Windows (version 11.5; SPSS Inc., Chicago, IL).
2 (Fisher exact, when appropriate) test was performed to examine relationship between categorical variables; results are not adjusted for multiple testing. The Mann-Whitney test was used to examine the possible relation between birth weight/gestational age/insulin/homeostasis model assessment and the parental origin of chromosome X. A t test was used to compare growth parameters and biochemical data between Xp and Xm patients. Analysis of covariance (ANCOVA) was used to adjust for age and body mass index (BMI), and results were compared with unadjusted analysis. Relation between patients pretreatment and on GH treatment used Wilcoxon signed ranks test. Correlation coefficients were calculated between continuous variables.
| Results |
|---|
|
|
|---|
The study group consisted of 83 females with TS and missing Xp, 66 of whom had 45,X karyotype, missing both Xp and Xq, and 14 of whom had 46Xi (Xq), missing Xp, but triploid for Xq genes. The parental origin of the single X chromosome was determined in 80 of 83 patients using the markers mentioned above (one sample was inadequate and in another two the results were inconclusive). No unexpected X mosaicism was found in any patient by the four X chromosome markers.
The most informative marker as to the parental origin was DXS1283 on Xp22.3 that was examined in 82 patients and was informative in 69 (84%); DYSII was informative in 82%, DMD49 in 73%, and androgen receptor of Xq locus in only 65% of the patients. Amplification of the Y chromosome revealed a single case with previously unknown positive SRY, but no other Y markers, in a 45,X patient, who retained her Xm.
Overall, the retained X chromosome was maternal (Xm) in 60 (75%) of the patients and paternal (Xp) in 20 (25%) patients; these data are consistent with previous reports (10, 11, 13). A significant difference was found between 45,X and 46Xi(Xq) subjects. A clear majority (83%) of the former retained their Xm, whereas 64% of the latter retained their Xp (P < 0.001). Yet none of the clinical data reported in the following paragraphs was found different between 45,X and 46Xi(Xq) subjects.
Clinical data
The mean age for the all group was 15.1 ± 7.0 yr (range 0.439 yr). The mean age for the Xm group was 13.9 ± 7.0 yr (range 0.439.5 yr) and 19.3 ± 5.5 yr in the Xp group (range 7.929.3 yr).
The difference in the paternal or maternal origin of the X chromosome did not influence the birth weight (2.87 ± 0.56 kg in Xp and 2.76 ± 0.55 kg in Xm) or gestational age (38.9 ± 1.6 and 39.1 ± 1.6 wk, respectively). The incidence of spontaneous puberty at the appropriate age was also similar in the two groups [Xp, two of 17 (11.7%), and Xm, five of 30 (16.6%); not significant (NS)]. Only one patient (Xm) gave spontaneous birth.
Hypertension and major anomalies of the heart did not differ according to parental origin of the X chromosome (Table 1
). Twenty percent of retained Xm and 35% of Xp had cardiac anomalies (NS); 8 and 15%, respectively, had hypertension in the absence of primary renal or cardiovascular cause. On the other hand, kidney malformations were an exclusive manifestation of Xm patients; 20% of the Xm patients and none of the Xp had renal anomalies (P = 0.030, Table 1
). When analyzed according to their karyotype, no significant differences were observed for any of the major physical anomalies.
|
|
|
Three of the TS patient with a 45,X karyotype had type 1 diabetes mellitus; two of them retained Xm and one retained Xp. One Xm patient had type 2 diabetes. Serum glucose, insulin, and homeostasis model assessment as a measure of insulin resistance were similar in the two groups and normal. The Xm group had lower total cholesterol (P < 0.004) and low-density lipoprotein (LDL) cholesterol (P < 0.05) than the Xp group (Table 4
). ANCOVA to age and BMI gave P = 0.003 for the total cholesterol and P = 0.045 for the LDL cholesterol.
|
The prevalence of fractures was identical in the two groups, and so was bone density by DXA, measured in 43 subjects above the age of available reference (Table 5
).
|
Sixty-two of the TS patients had been treated with recombinant human GH (hGH); 17 of them retained Xp (starting at age 10.8 ± 2.8 yr), and 45 retained Xm (starting at age 9.9 ± 3.1 yr; NS). None received anabolic steroids or additional drugs. GH dosage did not differ significantly between the groups (ranging from 0.04 to 0.34 mg/kg·d in the Xm and 0.03 to 0.36 in the Xp). Using the TS-specific growth charts (15), the pretreatment height SD score (SDS) was 0.25 ± 0.88 for Xp patients and +0.13 ± 0.99 in Xm patients (NS). Growth response was similar during the first year of GH treatment, and the current height and adult height of those who reached that point (eight patients in each group) did not differ as well. This remained true for each of the karyotype subgroups. The mean height gain (from initiating GH treatment to current height) was 1.49 ± 0.77 SDS in the Xp and 1.44 ± 1.00 SDS in the Xm group, subdividing this height gain in the years (till current age or
20 yr, the end of growth) gave the mean height gain per year. In the Xp patients (15), it was 0.289 ± 0.21 SDS each year, and in the Xm patients (42), it was 0.4 ± 0.31 SDS/yr (NS). Again analyzing these in the TS girls with 45,X karyotype only gave similar results without preferential growth response in either groups.
The BMI SDS during childhood and before hGH treatment was 0.2 ± 1.1 for Xp and 1.1 ± 1.9 for Xm groups (P = 0.030, Table 6
), and the most recent BMI SDS during this study was 0.9 ± 1.3 and 1.27 ± 1.8, respectively (NS). The percent of obese TS patients (BMI SDS > 2) was 33.3% in the Xp and 28.5% in the Xm group (NS).
|
We addressed two parameters by self- and parental reporting. Learning difficulties were evaluated by the need for special education; thereby, 23% of the TS patients had some degree of learning difficulties, 18.7% of the Xp, and 25% of the Xm patients (NS). The analysis of a subgroup of patients over the age of 20 yr revealed that twice as many Xp patient (five of seven, 76%) had academic skills or degrees, compared with Xm patients (four of 11, 36%); with its small sample size, these data are not significant statistically, but they lend support to a previous report (16).
Parental data
The mean maternal and paternal ages were 26.6 and 29.7 yr, respectively, with no difference between the Xm and Xp groups or their karyotype. The pretreatment height SDS correlated strongly in the Xp with the maternal and paternal height (r = 0.652 and 0.661, respectively (Table 7
). In the Xm patients, the correlation with paternal height (r = 0.525) was greater than the correlation with maternal height (r = 0.369).
|
|
| Discussion |
|---|
|
|
|---|
The multicenter design of this study was essential to assemble the largest ever number of subjects in this type of a study, but it also led to obvious difficulties in the rigor of clinical details. Even though, the small sample size made it difficult to have obtained enough power to detect mild differences, but the possibility to detect larger differences was attainable. To minimize these constraints, the clinical characterization was prospective; it was done by a single observer in each center, and they all used a unified table of more than 100 clinical features, which were later analyzed by the study coordinator. Although the age difference was significant statistically, its implication on each parameter studied is negligible in our opinion, even on the lipid profile. We admit to a possibility that some of the statistically significant results may be a spurious result of multiple testing. Physical stigmata diagnosed on the basis of imaging, such as heart defects, renal abnormalities, and bone mineralization defects were collected retrospectively or within the last year, but by different experts, with obvious possible discrepancy. We found no evidence of previously undetected mosaicism as far as four microsatellite markers can tell, but untested domain mosaicism can certainly not be fully excluded.
The overall frequency of abnormalities found in our sample group (independent of parental origin) was comparable with the prevalence reported in the literature for most of the abnormalities checked, total cardiac anomalies being on the lower range reported and renal anomalies found less frequently (Table 8
).
Preferential loss of Xp in this study, and others, and higher incidence of retained Xp in aborted fetuses (9) led to the hypothesis that deletion of the Xm may have a more profound phenotypic impact (5, 10, 16, 17). The present results reject this hypothesis; in fact, the current prospective study and a summary of most of the previous studies disclose that of the major phenotypic features, the prevalence of cardiac anomalies was similar in the two groups, whereas that of renal anomalies was greater in our Xm group but not so in previous reports. Due to significant heterogeneity among the cardiac and renal variables and small numbers in previous studies, it was impossible to give a total frequency.
Eye disorders were more prevalent in the Xp group (18). Whereas intrauterine lymphedema was believed to be related to prenatal death, none of the phenotypic features that are thought to be related to intrauterine lymphedema was found to stratify according to parental origin of the X chromosome, with the reservation of higher loss of Xp fetuses.
Using a mouse model for TS, a cluster of three X-linked genes was found to show transcriptional repression of paternal alleles (19). Imprinting of these three genes, Xlr3b, Xlr4b, and Xlr4c, is independent of X chromosome inactivation and has a dynamic and complex pattern of tissue and stage specificity. Xp-retaining XO mice are developmentally retarded and smaller than their XX controls, whereas Xm mice are larger than their XX controls on the 10th day of embryonic life (20). In humans, the opposite has been suggested: whereas the origin of the single X had no effect on general intelligence quotient, 45,X females with Xp chromosome had superior verbal and executive skills, compared with those with Xm chromosome (13). With a relatively small number of adult patients, the current study supports these findings: twice as many Xp patients had academic skills or degrees than Xm patients.
We also cannot support the findings in mice for a role for X chromosome imprinting in human postnatal growth or bone maturation and malformations, which are attributed partly to haploinsufficiency of the short stature homeobox SHOX gene at Xp22.3. Previous studies suggested a positive correlation between the final height of TS patients and that of their mothers (22) and a significant correlation with the maternal height and target height in Xm patients only (12, 23). A correlation of TS patients height with maternal and target height in both Xm and Xp subjects (8) was described in other reports. In the present study, Xm and Xp subjects had similar growth data. The same is true for the odds to develop spontaneous puberty. In Xm but not Xp patients, the correlation with paternal height was greater than the correlation with maternal height. On the other hand, Xm patients were significantly overweight, compared with the Xp group. Two obesity-related syndromes (Beckwith-Wiedemann and Prader-Willi syndromes) are subject to parental imprinting, but thus far no X chromosome imprinting has been implicated in obesity. The current results suggest that such a mechanism may yet to be discovered.
The fact that most of the patients in this study had been treated with hGH allowed us to compare relatively large groups of Xm and Xp TS patients response to treatment (24). To minimize possible influences of the differences in treatment regimes among the centers, we compared the mean of several variables and found no significant difference in pretreatment height, response to GH therapy, growth velocity in the first year of treatment, or final adult height. GH dosage did not differ significantly, and neither did the age at GH initiation. In the absence of a uniform GH treatment protocol, this is obviously incomplete, and further analysis of hGH treatment response is required. We did not find the suggested evidence of an X-linked imprinting effect on GH response as shown in a recent study (23).
Hypercholesterolemia has been demonstrated in TS girls as young as 11 yr and does not seem to be influenced by the karyotype or degree of obesity (25, 26). In this study 28% of the patients exhibited high total and LDL cholesterol levels; the levels were significantly higher in Xp subjects and did not correlate with BMI. The mean age difference of 4.2 yr between the groups exceeds the expected age-related rise in total and LDL cholesterol.
Insulin resistance did not stratify according to the origin of the retained X chromosome. These findings may suggest that the sexual dimorphic pattern of serum lipids is influenced by not only sex steroids but also an as-yet-undetermined X chromosome imprinting. A recent study on 89 elder TS patients had shown that monosomy for Xm chromosome was associated with greater visceral fat accumulation as measured by computed tomography and a more atherogenic lipid profile (higher triglycerides, total cholesterol, and LDL cholesterol) than monosomy for Xp (27). The wide age difference between the two study groups makes it difficult to compare, but this again supports the role of imprinted X linked genes in metabolic regulation.
With the data available on 208 TS patients studied so far (3, 4, 5, 6, 7, 8) including those of the present report, it may be a time for some conclusion on the impact of parental origin of the X chromosome on phenotypic findings. The parental origin of the X chromosome seems to have some impact on several phenotypic traits of TS, including overweight, kidney, eye, and lipids, which suggest a potential effect of as-yet-undetermined Xp arm gene/genes imprinting.
| Footnotes |
|---|
Disclosure Statement: The authors have nothing to disclose.
First Published Online December 27, 2006
Abbreviations: ANCOVA, Analysis of covariance; BMI, body mass index; DXA, dual-energy x-ray absorptiometry; hGH, human GH; LDL, low-density lipoprotein; NS, not significant; SDS, SD score; TS, Turner syndrome; Xm, maternally derived X chromosome; Xp, paternally derived X chromosome; Xp, short arm of chromosome X.
Received January 24, 2006.
Accepted December 19, 2006.
| References |
|---|
|
|
|---|
Read all eLetters
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |